Cardiac amyloidosis is a type of amyloidosis in which one of the affected organs is the heart. The disease is characterized by the formation of protein aggregates between the cells of the organ, namely amyloid, which disables its function. The following types of amyloidosis can be distinguished: systemic senile amyloidosis (wild-type ATTR), light chain amyloidosis (AL) and hereditary transthyretin-related amyloidosis. The symptoms include, e.g., systolic dysfunction or arrhythmia. The treatment is focused on the therapy with melphalan and, additionally, stem cells transplant and chemotherapy with dexamethasone or cyclophosphamide. In the advanced stage of the disease, a heart transplant is necessary. The diagnosis is made on the basis of laboratory testing, electrocardiogram changes, and echocardiography.

cardiac amyloidosis; amyloid; heart failure

FALK, Rodney H., et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. Journal of the American College of Cardiology, 2016, 68.12: 1323-1341.

MCCAUSLAND, Kristen L., et al. Cardiac biomarkers and health‐related quality of life in patients with light chain (AL) amyloidosis. British journal of haematology, 2018.

TUZOVIC, Mirela, et al. Cardiac amyloidosis: diagnosis and treatment strategies. Current oncology reports, 2017, 19.7: 46.

MOHTY, Dania, et al. Cardiac amyloidosis: updates in diagnosis and management. Archives of cardiovascular diseases, 2013, 106.10: 528-540.

RUBERG, Frederick L.; BERK, John L. Transthyretin (TTR) cardiac amyloidosis. Circulation, 2012, 126.10: 1286-1300.

DUBREY, S. W.; HAWKINS, P. N.; FALK, R. H. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart, 2011, 97.1: 75-84.

ANDO, Yukio, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet journal of rare diseases, 2013, 8.1: 31.

RAPEZZI, Claudio, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nature Reviews Cardiology, 2010, 7.7: 398.

MERLINI, Giampaolo; WECHALEKAR, Ashutosh D.; PALLADINI, Giovanni. Systemic light chain amyloidosis: an update for treating physicians. Blood, 2013, 121.26: 5124-5130.

GERTZ, Morie A. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. American journal of hematology, 2013, 88.5: 416-425.

GONZÁLEZ-LÓPEZ, Esther, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European heart journal, 2015, 36.38: 2585-2594.

BANYPERSAD, Sanjay M., et al. Updates in cardiac amyloidosis: a review. Journal of the American Heart Association, 2012, 1.2: e000364.

ESPLIN, Brandt L.; GERTZ, Morie A. Current trends in diagnosis and management of cardiac amyloidosis. Current problems in cardiology, 2013, 38.2: 53-96.

KAPOOR, Prashant, et al. Cardiac amyloidosis: a practical approach to diagnosis and management. The American journal of medicine, 2011, 124.11: 1006-1015

SHARMA, Nakul; HOWLETT, Jonathan. Current state of cardiac amyloidosis. Current opinion in cardiology, 2013, 28.2: 242-248.

JURCZYSZYN, A. ENGEL, M. RAJZER, J. CZEPIEL, G. MAZUR. Najnowsze postępy w rozpoznawaniu i leczeniu amyloidozy serca, Przegląd Lekarski, 2014, : 341.

ŻELICHOWSKI, Grzegorz. Diagnostyka amyloidozy układu sercowo-naczyniowego. Choroby Serca i Naczyń, 2010, 7.1: 40-48.

https://www.mp.pl/interna/chapter/B16.II.16.24.

CHARLIŃSKI, Grzegorz; JURYSZCZYN, A.; JĘDRZEJCZAK, W. W. Pierwotna, układowa amyloidoza łańcuchów lekkich–objawy kliniczne, aktualna diagnostyka i leczenie. Przegląd Lekarski, 2014, 2: 102-109.

OLESIŃSKA, Martyna, et al. Amyloidoza pierwotna AL z zajęciem serca. Folia Cardiologica, 2012, 7.4: 194-200.

ŻELICHOWSKI, Grzegorz; LUBAS, Arkadiusz; WAŃKOWICZ, Zofia. Postępy diagnostyki i leczenia AL amyloidozy. Pol Merk Lek, 2008, 142.24: 340-345.

AIMO, Alberto, et al. Therapies for cardiac light chain amyloidosis: An update. International journal of cardiology, 2018, 271: 152-160.

CIECHANOVER, Aaron. The ubiquitin–proteasome pathway: on protein death and cell life. The EMBO journal, 1998, 17.24: 7151-7160.

https://clinicaltrials.gov/ct2/show/NCT01659658.

GONZÁLEZ-LÓPEZ, Esther; LÓPEZ-SAINZ, Ángela; GARCIA-PAVIA, Pablo. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and Hope. Revista Española de Cardiología (English Edition), 2017, 70.11: 991-1004.

MAURER, Mathew S., et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 2018, 379.11: 1007-1016.

MILANI, Paolo; MERLINI, Giampaolo; PALLADINI, Giovanni. Novel therapies in light chain amyloidosis. Kidney international reports, 2018, 3.3: 530-541.

CHAKRABORTY, Rajshekhar; MUCHTAR, Eli; GERTZ, Morie A. Newer therapies for amyloid cardiomyopathy. Current heart failure reports, 2016, 13.5: 237-246.

CRUZ, Márcia Waddington; BENSON, Merril D. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neurology and therapy, 2015, 4.2: 61-79.